- Improved response rate and longer duration of response
- TG4010 shows activity in patients with low PD-L1 expressing tumors
Strasbourg, France, June 1, 2015 – Transgene SA (Euronext: TNG) today announced the presentation of new data from the Phase 2b part of the TIME trial with the TG4010 MUC1 targeted immunotherapy in non-small cell lung cancer (NSCLC) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL USA.
The more mature data confirmed the strength of the previously reported improvements in progression-free survival (PFS) and overall survival (OS), particularly in patients with non-squamous tumors. In addition, patients treated with TG4010 plus chemotherapy demonstrated improved response rates and a longer median duration of response compared to the control group.
Also of note, in a retrospective analysis of PD-L1 expression in patient tumor cells from the trial, strong activity was seen with TG4010 in patients having low levels (
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||3.1200||0.48%||14 655|